Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URIEXO Attack+ is an over-the-counter natural health product formulated to support urinary tract health and prevent recurrent urinary tract infections (UTIs) and cystitis. Developed by Tyros Biopharma, each daily dose delivers a combination of clinical-strength D-mannose (2000 mg) and vitamin C (75 mg). D-mannose serves as a competitive inhibitor that binds to the FimH adhesin on the type 1 fimbriae of uropathogenic Escherichia coli (UPEC), preventing the bacteria from adhering to the urothelium and allowing them to be flushed out during urination. Vitamin C provides antioxidant protection, supports immune function, and helps acidify the urine, creating an environment less favorable to bacterial proliferation. This non-antibiotic approach offers a proactive defense against recurrent UTIs without contributing to antibiotic resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uriexo Attack+.